ProPublica |
Overuse, Safety Questions Cloud Advair's Ascent to Asthma Blockbuster
ProPublica The asthma drug has generated more than $80 billion in global revenues for its maker, GlaxoSmithKline, since its U.S. approval in 2000. With its distinctive purple inhaler, Advair has helped legions of asthma sufferers achieve control of their symptoms. |
View full post on asthma – Google News